Drugs / Gemcitabine
Gemcitabine
Drug FDA approvedAntimetabolite (nucleoside analogue)·First approved·1996
- Registered trials
- 1488
- Ongoing
- 387/ 26%
- Completed
- 679
- Indications
- 5
Approved indications
| Indication |
|---|
| Pancreatic cancer |
| Non-small cell lung cancer |
| Breast cancer |
| Ovarian cancer |
| Bladder cancer |
Clinical trial landscape
1488 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 2 | 689 | 164 | 336 | |
| Phase 3 | 262 | 105 | 96 | |
| Phase 1 | 260 | 41 | 141 | |
| Phase 1/2 | 187 | 45 | 81 | |
| Phase 2/3 | 36 | 19 | 10 | |
| Not applicable | 19 | 8 | 3 | |
| Unknown | 14 | 1 | 7 | |
| Early Phase 1 | 13 | 2 | 4 | |
| Phase 4 | 8 | 2 | 1 | |
| All phases | 1488 | 387 | 679 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Blocks creation of new DNA; incorporation into DNA leads to inhibition of further DNA synthesis and cell death.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.